Rodrigo Alcantara

Rodrigo Alcantara

Auto-generated profile, based on publicly available information

Rodrigo Alcantara

Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2022 in European Radiology
Verified
Journal Article
Open access
PDF file
RAR. Alcantara
R. Alcantara
MPM. Posso
M. Posso
MPM. Pitarch
M. Pitarch
NAN. Arenas
N. Arenas
BEB. Ejarque
B. Ejarque
GBG. Besutti
G. Besutti
Objectives: To evaluate the feasibility of contrast-enhanced mammography (CEM)-guided biopsy at Hospital del Mar, a Spanish university hospital. Methods: We retrospectively reviewed all consecutive women with a suspicious enhancing finding eligible for CEM-guided biopsy, who were prospectively enrolled in a pre-marketing clinical validation and feasibility study (October 2019 to September 2021). CEM-guided biopsy is a stereotactic-based procedure that, by using intravenous iodinated contrast media administration and dual-energy acquisition, provides localisation of enhancing lesions. All the biopsies were performed using a vacuum-assisted device. We collected procedural characteristics (patient position and type of approach), and histopathological results. Feasibility endpoints included success (visualisation of the enhancing lesion, post-procedural biopsy changes and clip placement), procedural time, number of scout acquisitions and complications. Results: A total of 66 suspicious enhancing lesions (18.0% foci, 44.0% mass, 38.0% non-mass enhancement; median size 8.5 mm) in 64 patients (median age 59 years, mostly minimal [48.4%] or mild [32.8%] background parenchymal enhancement) were referred for CEM-guided biopsy in the study period. The success rate was 63/66 (95.4%). Amongst successful procedures, patients were most frequently seated (52/63, 82.5%) and the preferred approach was horizontal (48/63, 76.2%). Median total time per procedure was 15 min. Median number of acquisitions needed before targeting was 2 (range 1–4). Complications consisted of hematoma (17/63, 27%) and vasovagal reaction (2/63, 3.2%). At histology, the malignancy rate was 25/63 (39.7%). Conclusion: In this first patient series, CEM-guided breast biopsy was feasible, with success and complication rates similar to those previously reported for magnetic resonance guidance. Key points: • CEM may be used to guide biopsy of enhancing lesions through a stereotactic-based procedure combined with intravenous iodinated contrast media administration and dual-energy acquisition. • In this first patient series (n = 64), the success rate of CEM-guided biopsy was above 95%, the only complications were hematoma (22.2%) and vasovagal reaction (3.2%), and median total time per procedure was 15 min. • CEM-guided biopsy is feasible and could potentially be a widely available biopsy technique for enhancing-only lesions.

1 December 2020 in The Breast
Verified
Journal Article
Open access
JLJavier Louro
Javier Louro
MRMarta Román
Marta Román
MPMargarita Posso
Margarita Posso
LCLaura Comerma
Laura Comerma
CLCarmen Vidal Lancis
Carmen Vidal Lancis
XCXavier Castells
Xavier Castells
We aimed to assess differences in breast cancer risk across benign breast disease diagnosed at prevalent or incident screens. We conducted a retrospective cohort study with data from 629,087 women participating in a long-standing population-based breast cancer screening program in Spain. Each benign breast disease was classified as non-proliferative, proliferative without atypia, or proliferative with atypia, and whether it was diagnosed in a prevalent or incident screen. We used partly conditional Cox hazard regression to estimate the adjusted hazard ratios of the risk of breast cancer. Compared with women without benign breast disease, the risk of breast cancer was significantly higher (p-value = 0.005) in women with benign breast disease diagnosed in an incident screen (aHR, 2.67; 95%CI: 2.24-3.19) than in those with benign breast disease diagnosed in a prevalent screen (aHR, 1.87; 95%CI: 1.57-2.24). The highest risk was found in women with a proliferative benign breast disease with atypia (aHR, 4.35; 95%CI: 2.09-9.08, and 3.35; 95%CI: 1.51-7.40 for those diagnosed at incident and prevalent screens, respectively), while the lowest was found in women with non-proliferative benign breast disease (aHR, 2.39; 95%CI: 1.95-2.93, and 1.63; 95%CI: 1.32-2.02 for those diagnosed at incident and prevalent screens, respectively). Our study showed that the risk of breast cancer conferred by a benign breast disease differed according to type of screen (prevalent or incident). To our knowledge, this is the first study to analyse the impact of the screening type on benign breast disease prognosis.

14 August 2024 in European Radiology
Verified
Journal Article
Open access
PDF file
RARodrigo Alcantara
Rodrigo Alcantara
JAJavier Azcona
Javier Azcona
MPMireia Pitarch
Mireia Pitarch
NANatalia Arenas
Natalia Arenas
XCXavier Castells
Xavier Castells
GBGiulia Besutti
Giulia Besutti
Objectives: This retrospective study aimed to compare the average glandular dose (AGD) per acquisition in breast biopsies guided by contrast-enhanced mammography (CEM), conventional stereotactic breast biopsy (SBB), and digital breast tomosynthesis (DBT). The study also investigated the influence of compressed breast thickness (CBT) and density on AGD. Furthermore, the study aimed to estimate the AGD per procedure for each guidance modality. Methods: The study included 163 female patients (mean age 57 ± 10 years) who underwent mammography-guided biopsies using SBB (9%), DBT (65%), or CEM (26%) guidance. AGD and CBT data were extracted from DICOM headers, and breast density was visually assessed. Statistical analyses included two-sample t-tests and descriptive statistics. Results: Mean AGD per acquisition varied slightly among CEM (1.48 ± 0.22 mGy), SBB (1.49 ± 0.40 mGy), and DBT (1.55 ± 0.47 mGy), with CEM presenting higher AGD at lower CBTs and less dose escalation at higher CBTs. For CBT > 55 mm, CEM showed reduced AGD compared to SBB and DBT (p < 0.001). Breast density had minimal impact on AGD, except for category A. The estimated AGD per procedure was approximately 11.84 mGy for CEM, 11.92 mGy for SBB, and 6.2 mGy for DBT. Conclusion: The study found mean AGD per acquisition to be similar for CEM and SBB, with DBT slightly higher. CEM demonstrated higher AGD at lower CBT but lower AGD at higher CBT, indicating reduced dose escalation with increasing thickness. While breast density had minimal overall impact, variations were noted in category A. DBT was more dose-efficient per procedure due to fewer acquisitions required. Clinical relevance statement: CEM guidance provides effective lesion visualization within safe radiation limits, improving the precision of percutaneous image-guided breast interventions and supporting its potential consideration in a wider range of breast diagnostic procedures. Key Points: Limited data exist on the AGD using CEM guidance for breast biopsies. CEM and SBB exhibit similar AGD per acquisition; DBT demonstrated the lowest AGD per procedure. Radiation from CEM guidance fits within safe limits for percutaneous image-guided breast interventions. Graphical

16 July 2025 in European Journal of Radiology
Verified
Journal Article
Open access
JSJavier Azcona Sáenz
Javier Azcona Sáenz
PBPascal A.T. Baltzer
Pascal A.T. Baltzer
IAIris Allajbeu
Iris Allajbeu
ARAllison Rose
Allison Rose
EAErkin Aribal
Erkin Aribal
TNThiemo J.A. van Nijnatten
Thiemo J.A. van Nijnatten
To perform an international survey among global expert breast radiologists regarding contrast-enhanced mammography (CEM) on the topic of reimbursement strategies. An online questionnaire on CEM reimbursement strategies was distributed to 29 selected global expert breast radiologists regarding CEM. Hospital information, CEM implementation, estimated costs, reimbursement availability, registration and declaration codes, as well as personal opinions on CEM reimbursement, were collected. Replies were analyzed using descriptive and non-parametric statistics. Twenty out of 29 global expert breast radiologists regarding CEM responded to this survey. All respondents had implemented CEM at their hospitals between 2011 and 2024 and offered CEM for clinical/diagnostic indications, CEM price ranges were lower than MRI at all but two sites. Sixty percent of hospitals (12/20) reported receiving reimbursement for CEM. The remaining 40% declared not receiving reimbursement, citing reasons such as coverage by department budget, lack of dedicated billing code, or absence of reimbursement by the national healthcare system and/or insurance providers. Among the 12 hospitals receiving reimbursement, 67% (8/12) obtained full reimbursement for all components of CEM, and 75% (9/12) for all indications. Reimbursement sources varied by hospital type, with public and university hospitals mainly publicly funded, and private hospitals relying on insurance or patient payments. Most respondents (75%, 15/20) reported that no dedicated national reimbursement code for CEM currently exists. Of these respondents, 53% (8/15) used the FFDM code. Most hospitals lacked separate codes for the contrast medium (60%, 9/15) or its intravenous injection (93.3%, 14/15). Among hospitals without a national code, 73% (11/15) were aware of efforts to establish one. Although nearly half of the participants (45%, 9/20) faced reimbursement challenges, 65% (13/20) stated that reimbursement strategies did not affect their CEM adoption. Substantial heterogeneity in CEM reimbursement strategies exist, with most hospitals securing full coverage through alternative strategies until dedicated national reimbursement codes are established.

24 November 2025 in Insights into Imaging
Verified
Journal Article
Open access
RARodrigo Alcantara
Rodrigo Alcantara
JAJavier Azcona
Javier Azcona
MPMireia Pitarch
Mireia Pitarch
EVElisenda Vall
Elisenda Vall
EVElisabet Vila-Trias
Elisabet Vila-Trias
EAE. Natalia Arenas
E. Natalia Arenas
Contrast-enhanced mammography (CEM)-guided biopsy enables the tissue sampling of enhancing breast lesions that are not visible on conventional imaging. The technique combines dual-energy stereotactic acquisition with intravenous contrast administration, allowing accurate targeting of recombined-only lesions. It represents a practical alternative to MRI-guided biopsy, particularly in settings where MRI access is limited or contraindicated. This review examines current evidence, procedural experience, and challenges associated with CEM guidance. Early studies support its technical feasibility, although data remain scarce and heterogeneous regarding lesion selection, procedural experience, and outcome definitions. Broader implementation is challenged by equipment specifications, contrast administration practices, logistics, and reimbursement issues. As clinical adoption increases, structured patient triage pathways, standardised protocols, and prospective validation are essential. CEM-guided biopsy is a promising technique in breast imaging and has the potential to reduce reliance on MRI guidance. However, further research is required to define its role and ensure consistent performance across clinical settings. Critical relevance statement: This review critically examines current evidence, technical feasibility, and implementation challenges of contrast-enhanced mammography-guided biopsy. It highlights potential advantages for clinical settings where MRI guidance is limited, while addressing existing limitations and areas that require further research. Key Points: Contrast-enhanced mammography-guided biopsy is a dual-energy stereotactic procedure that enables the targeting of enhancing lesions that lack conventional imaging correlates. The modality is accurate and feasible, though its implementation is challenged by technical heterogeneity and the absence of standardised protocols. Broader clinical adoption requires structured diagnostic workflows, validated contrast administration strategies, and prospective multicentre evaluation. Graphical

1 November 2025 in Radiology
Verified
Journal Article
Closed access
ACAndrea Cozzi
Andrea Cozzi
CBChiara Bellini
Chiara Bellini
RGRossano Girometti
Rossano Girometti
RSRodrigo Alcántara Souza
Rodrigo Alcántara Souza
GPGianmarco Della Pepa
Gianmarco Della Pepa
SSSimone Schiaffino
Simone Schiaffino
In a multicenter retrospective study, contrast-enhanced mammography showed high specificity for preoperatively ruling in pathologic nipple involvement in patients with breast cancer, allowing surgeons and patients to choose nipple-sparing surgery.